Pharmacokinetics, pharmacodynamics, safety, and tolerability of act-539313, a novel selective orexin-1 receptor antagonist, in a first-in-human study

Authors
Category Primary study
ConferenceClinical Pharmacology and Therapeutics
Year 2018
This article has no abstract
Epistemonikos ID: 4496b045cc2186c1cbd6de1052680d23ff5f717e
First added on: Apr 29, 2026